Description: IMMUcan, an integrated European immuno-oncology profiling platform Immune checkpoint inhibitors have shown promising results in some cancer types, but biomarkers to select patients that might respond to the treatment are still missing. Similarly, rationales for combining immune checkpoint inhibitors with conventional therapy or targeted agents are lacking. Read more
Immune checkpoint inhibitors have shown promising results in some cancer types, but biomarkers to select patients that might respond to the treatment are still missing. Similarly, rationales for combining immune checkpoint inhibitors with conventional therapy or targeted agents are lacking.
2023-02-01T14:49:11+01:00 March 30th, 2022 |
March marked an important month in the campaign to [...]